drugset / Trial / NCT05361668
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.
Timeline
- Start
- 2022-04-22
- Primary completion
- 2024-03-07
- Completion
- 2026-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paltusotine | Small molecule | 40 mg | Oral |
| Subject | Paltusotine | Small molecule | 80 mg | Oral |